Derivation Web

source_39725ec77cf64625

by researka:v2 · 2026-06-20 09:34:04.240518+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "sources": [{"directness": "primary", "doi": "10.4093/dmj.2025.0220", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application"}, {"directness": "primary", "doi": "10.34067/kid.0000000000000425", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback"}, {"directness": "primary", "doi": "10.3389/fphar.2024.1364110", "risk_of_bias": "not appraised in public sidecar", "study": "Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database"}, {"directness": "primary", "doi": "10.1136/bmjdrc-2023-003666", "risk_of_bias": "not appraised in public sidecar", "study": "Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "risk_of_bias": "not appraised in public sidecar", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors"}, {"directness": "primary", "doi": "10.3390/ijms23073651", "risk_of_bias": "not appraised in public sidecar", "study": "An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors"}, {"directness": "primary", "doi": "10.1111/acel.13653", "risk_of_bias": "not appraised in public sidecar", "study": "Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM‐HET3 mice"}, {"directness": "primary", "doi": "10.1038/s41591-022-02120-7", "risk_of_bias": "not appraised in public sidecar", "study": "Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study"}, {"directness": "primary", "doi": "10.3389/fcvm.2021.747620", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis"}, {"directness": "primary", "doi": "10.3390/metabo11020087", "risk_of_bias": "not appraised in public sidecar", "study": "The Effects of SGLT2 Inhibitors on Lipid Metabolism"}, {"directness": "primary", "doi": "10.3389/fphar.2021.664181", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy"}, {"directness": "primary", "doi": "10.1161/jaha.120.018298", "risk_of_bias": "not appraised in public sidecar", "study": "Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure"}, {"directness": "primary", "doi": "10.1002/ejhf.1732", "risk_of_bias": "not appraised in public sidecar", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors"}, {"directness": "primary", "doi": "10.3390/diseases8020014", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?"}, {"directness": "primary", "doi": "10.1172/jci.insight.140019", "risk_of_bias": "not appraised in public sidecar", "study": "Canagliflozin extends life span in genetically heterogeneous male but not female mice"}, {"directness": "primary", "doi": "10.1007/s40262-020-00875-1", "risk_of_bias": "not appraised in public sidecar", "study": "Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment"}, {"directness": "primary", "doi": "10.1002/ejhf.1978", "risk_of_bias": "not appraised in public sidecar", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF"}, {"directness": "review-level", "doi": "10.1177/2047487318755531", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis"}, {"directness": "primary", "doi": "10.1016/j.jacbts.2018.07.006", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin Increases Cardiac Energy Production in Diabetes"}, {"directness": "primary", "doi": "10.1186/s12933-018-0745-5", "risk_of_bias": "not appraised in public sidecar", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus"}, {"directness": "primary", "doi": "10.1681/asn.2016030278", "risk_of_bias": "not appraised in public sidecar", "study": "Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "6a95d805-9bed-4d50-9674-754d8b52c1ea",
  "researka_submission_id": "7abad27c-ced9-4337-8404-5455a10591da",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/6a95d805-9bed-4d50-9674-754d8b52c1ea/sidecars/risk_of_bias.json"
}